tirzepatide surpass cvot SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I ๐ก New insight in diabetes
Pay in 4 interest-free payments of $5.50 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Jul 31 - Aug 5


01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)



















